This fratricide can be abrogated, for example, by KO of CD7 or CD5 before transduction with CARs targeting these respective antigens.74,75 Such genome editing to circumvent fratricide is currently being evaluated in patients with hematologic malignancies (NCT04264078) and treated with CD7-redirected CAR-T cells with disrupted CD7 and TRAC genes. Here, CD7 is linked to hematologic disorder.